(Q37693672)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20160743%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Biosimilars: evidential standards for health technology assessment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20160743%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20160743%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

D A Hughes

series ordinal

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20160743%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20160743%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20160743%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20160743%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

257-261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20160743%20AND%20SRC:MED&resulttype=core&format=json

Economic issues with follow-on protein products.

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

Immunogenicity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

Pure red cell aplasia due to follow-on epoetin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

The death of cost-minimization analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

Practical guidelines for economic evaluations alongside equivalence trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

NICE and new: appraising innovation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

Toward biosimilar monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

inferred from DOI database lookup

7 January 2021

based on heuristic

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112

inferred from DOI database lookup

7 January 2021

based on heuristic

Interchangeability of off-patent medicines: a pharmacoeconomic perspective

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.112